Bowe Frances, Lavelle Ed C, McNeela Edel A, Hale Christine, Clare Simon, Arico Beatrice, Giuliani Marzia M, Rae Aaron, Huett Alan, Rappuoli Rino, Dougan Gordon, Mills Kingston H G
Centre for Molecular Microbiology and Infection, Department of Biological Sciences, Imperial College of Science, Technology and Medicine, London, UK.
Infect Immun. 2004 Jul;72(7):4052-60. doi: 10.1128/IAI.72.7.4052-4060.2004.
Conjugated polysaccharide vaccines protect against serogroup C meningococci. However, this approach cannot be applied to serogroup B, which is still a major cause of meningitis. We evaluated the immunogenicity of three surface-exposed proteins from serogroup B Neisseria meningitidis (App, NhhA, and NadA) identified during whole-genome sequencing. Mice were immunized intranasally with individual proteins in the presence of wild-type Escherichia coli heat-labile enterotoxin (LTwt), LTR72, a partially inactivated mutant, or LTK63, a completely nontoxic mutant, as the adjuvant. Each of the meningococcal proteins induced significant cellular responses; NhhA and NadA induced strong antibody responses, but only NadA induced bactericidal antibody when administered intranasally with mucosal adjuvants. In addition, immunoglobulin A and bactericidal antibodies were detected in the respiratory tract following intranasal delivery of NadA. Analysis of antigen-specific cytokine production by T cells from immunized mice revealed that intranasal immunization with NadA alone failed to generate detectable cellular immune responses. In contrast, LTK63, LTR72, and LTwt significantly augmented NadA-specific gamma interferon, interleukin-4 (IL-4), IL-5, and IL-10 production by spleen and lymph node cells, suggesting that both Th1 and Th2 cells were induced in vivo. The strongest cellular responses and highest bactericidal antibody titers were generated with LTR72 as the adjuvant. These findings demonstrate that the quality and magnitude of the immune responses generated by mucosal vaccines are influenced by the antigen as well as the adjuvant and suggest that nasal delivery of NadA with mucosal adjuvants has considerable potential in the development of a mucosal vaccine against serogroup B meningococci.
结合多糖疫苗可预防C群脑膜炎奈瑟菌。然而,这种方法不适用于B群,而B群仍是脑膜炎的主要病因。我们评估了在全基因组测序过程中鉴定出的B群脑膜炎奈瑟菌三种表面暴露蛋白(App、NhhA和NadA)的免疫原性。在野生型大肠杆菌不耐热肠毒素(LTwt)、部分失活突变体LTR72或完全无毒突变体LTK63作为佐剂的情况下,用单个蛋白经鼻免疫小鼠。每种脑膜炎球菌蛋白均诱导了显著的细胞反应;NhhA和NadA诱导了强烈的抗体反应,但只有NadA与黏膜佐剂经鼻给药时诱导了杀菌抗体。此外,经鼻递送NadA后,在呼吸道中检测到了免疫球蛋白A和杀菌抗体。对免疫小鼠T细胞产生的抗原特异性细胞因子的分析表明,单独经鼻免疫NadA未能产生可检测到的细胞免疫反应。相比之下,LTK63、LTR72和LTwt显著增强了脾脏和淋巴结细胞产生的NadA特异性γ干扰素、白细胞介素-4(IL-4)、IL-5和IL-10,表明体内诱导了Th1和Th2细胞。以LTR72作为佐剂时产生了最强的细胞反应和最高的杀菌抗体滴度。这些发现表明,黏膜疫苗产生的免疫反应的质量和强度受抗原以及佐剂的影响,并表明用黏膜佐剂经鼻递送NadA在开发针对B群脑膜炎奈瑟菌的黏膜疫苗方面具有相当大的潜力。